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of vertebral fractures and death among Australian patients with corticosteroid-induced 
osteoporosis. Age-speciﬁ c underlying incidences of vertebral fractures and death were 
estimated from published data. The costs (AUD $1393 in Year 1 and AUD $34 in 
subsequent years) and utility (0.71) associated with a vertebral fracture were also 
drawn from published sources, as was the efﬁ cacy of risedronate in reducing vertebral 
fracture risk (relative risk 0.43, 95% CI 0.20–0.92). The model adopted a life-time 
horizon and an annual discount rate of 5% was applied to both costs and years of 
life/QALYs lived. Multiple sensitivity analyses were undertaken with reasonable varia-
tions to key data inputs. RESULTS: The base-case incremental cost-effectiveness ratio 
(ICER) with a life-time horizon was AUD $18,085 per QALY saved. Estimated ICERs 
remained below AUD $40,000 per QALY saved throughout all sensitivity analyses, 
except when assuming the upper limit of the 95% conﬁ dence interval for risedronate’s 
efﬁ cacy in reducing vertebral fracture risk (AUD $53,130 per QALY saved). CON-
CLUSIONS: Risedronate represents a cost-effective option for preventing vertebral 
fractures in Australian patients with corticosteroid-induced osteoporosis. This was 
conﬁ rmed by the recent recommendation by the Australian Pharmaceutical Beneﬁ ts 
Advisory Committee (PBAC) that risedronate be reimbursed for this indication. 
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
PMS9
HEALTH-RELATED QUALITY OF LIFE IN INDIAN PATIENTS WITH 
RHEUMATOID ARTHRITIS
Khera K, Nagappa AN, Thunga G, Sam K
Manipal College of Pharmaceutical Sciences, Manipal, India
OBJECTIVES: Rheumatoid arthritis (RA) is a multisystem disease with various extra-
articular manifestations (EAMs). Health-related quality of life (HRQOL) issues are 
assuming increasing importance in chronic rheumatic diseases like RA. Very less data 
on QOL in RA is available from the Indian subcontinent. There is also a paucity of 
literature on the impact of EAMs on HRQOL in RA. The objective of this study was 
to address these lacunae. METHODS: The study group comprised 166 patients with 
RA from a rheumatology clinic in India. Quality of life was estimated by the generic 
HRQOL measure: World Health Organization quality of life instrument (WHOQOL-
Bref). Disease activity in RA was measured by calculating Disease Activity Score-28 
(DAS28) and functional disability by the Health Assessment Questionnaire (HAQ). 
Extra-articular manifestations (EAMs) were diagnosed clinically. RESULTS: The 
mean duration of rheumatoid arthritis (RA) was 10 ± 3.1 years. The mean DAS28 
and HAQ were 4.21 ± 1.1 and 1.01 ± 1.2, respectively. At least one ExRA was present 
in 46 patients. The mean HRQOL scores of the patients were 11.5 +/− 2.1, 12.2 
+/− 2.5, 13.4 +/− 2.6, and 12.3 +/− 2.4 in the physical, psychological, social, and 
environmental domains of the WHOQOL-Bref respectively. Age, gender, disease dura-
tion, educational status, constitutional symptoms, rheumatoid factor positivity, ero-
sions and deformities did not inﬂ uence HRQOL. Disease activity had a negative 
inﬂ uence on the physical and psychological domains. Patients with EAMs had signiﬁ -
cantly higher DAS28 scores compared to patients without EAMs. Even after adjust-
ment for disease activity, patients with EAMs had lower HRQOL scores than patients 
without these features (statistically signiﬁ cant for physical domain). CONCLUSIONS: 
The physical domain of HRQOL is most affected in Indian patients with RA. Increas-
ing disease activity and presence of EAMs worsens the quality of life. 
MUSCULAR-SKELETAL DISORDERS – Health Care Use & Policy Studies
PMS10
HEALTH-CARE UTILIZATION OF NEW PATIENTS WITH LOW BACK 
PAIN IN SOUTH KOREA
Kim JH, Lee SM, Cheong C, Jang B, Son HJ
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: The purpose of this study was to describe the pattern of health-care 
utilization among new patients with low back pain. METHODS: This study is based 
on the Korean National Health Insurance (NHI) claim data. Study subjects included 
those who 1) were newly diagnosed as low back pain; 2) received at least one lum-
bosacral spine simple x-ray; and 3) were not using medical service as a patient with 
low back pain for past 2 years before the ﬁ rst visit (index date). The follow-up period 
was 1 year from the index date. RESULTS: New patients with low back pain used 
the clinic (81.8%) most and orthopedics (62.2%) was the most visited department in 
2006. Ninety-six percent of new patients used outpatient service and 5.9% used 
inpatient service. The medical cost (paid by insurers) per patient was $215.1. Male 
expenses more than female, and the cost increased as the age of patients increased. 
Average days including medication days and days of visit per new patient with low 
back pain was 6.7 days with the tendency that female’s average days including medica-
tion days and days of visit were more than those of male’s. In terms of outpatient 
service, average days including medication days and days of visit per new patients was 
5.8 days and in inpatient service, it was 15.8 days. CONCLUSIONS: Efforts to 
identify the factors which may produce low back pain and to reduce the incidence is 
on need. Also, analysis on the factors inﬂ uential over the health-care use of new 
patients with low back pain needs to be conducted in future studies. 
PMS11
HEALTH-CARE UTILIZATION OF PATIENTS WITH LOW BACK PAIN IN 
SOUTH KOREA (2006–2008)
Kim JH, Lee SM, Cheong C, Jang B, Son HJ
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: The objectives of this study were 1) to identify the pattern of health-
care use; and 2) to estimate the pattern change of health-care use for low back pain 
in each year of 2006, 2007, and 2008. METHODS: This study is based on the Korean 
National Health Insurance (NHI) claim data. Study subjects included those who 1) 
used medical service as a patient with low back pain from January 1 to December 31, 
and 2) received at least one lumbosacral spine simple x-ray each year. The identiﬁ ed 
number of the patients was 1,981,427 in 2006, 2,069,995 in 2007, and 2,119,408 in 
2008. RESULTS: Patients with low back pain used the clinic most and orthopedics 
was the most visited department in each year of 2006, 2007, and 2008. The rate of 
outpatient service use declined and that of inpatient service use increased in compared 
3 years. The medical cost (paid by insurers) showed increasing trend estimated as $569 
million in 2006, $626 million in 2007, and $654 million in 2008. However, if the 
inﬂ ation rate of consumer price was considered (2.4% going up between 2006 and 
2007, and 7.3% between 2006 and 2008), the cost in 2007 was estimated as $611 
million still showing increase, but, in 2008, $610 million was estimated showing 
decrease. Medical cost per patient was $287.2 in 2006, $295.2 in 2007, and $287.8 
in 2008. Average days including medication days and days of visit per patient was 9.4 
days in 2006, 9.1 days in 2007, and 8.8 days in 2008 as declining. CONCLUSIONS: 
Efforts are needed to reduce prevalence and incidence of low back pain. And analysis 
on factors inﬂ uential on the medical use of the patients needs to be conducted in future 
studies. 
PMS12
INCREASE OF INJECTION THERAPY ON PATIENTS WITH LOW BACK 
PAIN IN SOUTH KOREA (2006–2008)
Kim JH, Lee SM, Cheong C, Jang B, Son HJ
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: The purposes of this study were 1) to analyze the pattern of injection 
therapy use for low back pain, and 2) to estimate the health-care use of low back pain 
patient who received injection therapy in 2006, 2007, and 2008. METHODS: This 
study is based on the Korean National Health Insurance (NHI) claim data. Study 
subjects included those who 1) used medical service as a patients with low back pain 
from January 1 to December 31; 2) received at least one lumbosacral spine simple 
x-ray; and 3) took more than one injection therapy each year. RESULTS: The percent 
of patients with low back pain who received injection therapy was increasing as fol-
lowed: 10.8% in 2006 (213,796 among total 1,981,427 patients with low back pain), 
11.0% in 2007 (227,432 among 2,069,995), and 11.5% (244,640 among 2,119,408). 
Number of patients with low back pain treated with injections per 100,000 general 
population was 436 in 2006, 462 in 2007, and 494 in 2008. Number of patients with 
low back pain treated with injections per 100,000 low back pain patients was 10,790 
in 2006, 10,987 in 2007, and 11,543 in 2008. The rate of patients who received one 
injection in a year was 58.9% in 2006, 52.5% in 2007, and 48.1% in 2008 showing 
tendency of decrease, while more than two injections was increasing. The most con-
ducted procedure was Epidural Nerve Blocks consistently for 3 years. The most 
department visited for service was anesthesiology in 2006 and orthopedics in 2007 
and 2008. CONCLUSIONS: The injection therapy on patients with low back pain is 
increasing. But the efﬁ cacy of it has not reached to consensus so far, which means 
more careful conducting is needed. Also, the efﬁ cacy of injection therapy speciﬁ cally 
in South Korea should be investigated in future studies. 
PMS14
FACTORS INFLUENCED ORAL OXICAM AND COXIBS’ EXPENDITURE 
AT A THAI TEACHING HOSPITAL, FISCAL YEAR 2006–2009
Kaojarern S1, Masaya-anon N1, Pongcharoensuk P2, Pattanaprateep O1
1Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Mahidol University, Bangkok, 
Thailand
OBJECTIVES: Oral Oxicam and Coxibs’ expenditure at a Thai teaching hospital was 
rapidly increased in recent years. We examined price and quantity factors that inﬂ u-
enced the rising expenditure by deterministic model. METHODS: This study was a 
retrospective database analysis at a Thai teaching hospital in Bangkok. Prescription 
utilization data of one oral Oxicam and two Coxibs (Meloxicam, Celecoxib, and 
Etoricoxib) during ﬁ scal year 2006 to 2009 were retrieved. In the model, changes in 
annual expenditure were attributed to two factors: cost per patient per year (P) and 
number of patients per year (Q). By measuring quantity as Deﬁ ned Daily Dose (DDD), 
changes in cost per patient (P) comprised of two parts: cost per DDD (p) and DDD 
per patient (q). RESULTS: Overall expenditure of the three drugs was risen from 49.9 
million Baht in 2006 to 64.9 million Baht in 2009 (adjusted for inﬂ ation). Thirty 
percent of total increase in expenditure was mainly the result of switching from 
Meloxicam (percent change, −44%) to Etoricoxib (119%). When decomposed into 
price and quantity factors, quantity had more effect than price, especially number of 
patients who moved from Meloxicam (percent change of Q, −35%) to Etoricoxib 
(112%) and Celecoxib (8%). DDD per patient for Celecoxib was a little increase 
(percent change of q, 4%), slightly decreased for Etoricoxib (−4%), and much lower 
for Meloxicam (−32%). Percent change in price of the three drugs was slightly positive 
(28%, 7%, and 8% for Meloxicam, Celecoxib, and Etoricoxib, respectively). CON-
CLUSIONS: The major increase of drug expenditure from 2006 to 2009 was from 
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patients switching from older drug, Oxicam to new drugs, Coxibs. Deterministic 
model will help the hospital administrator understand pattern of drug use and its effect 
of ﬁ nancial management; however, clinical outcome should be included for further 
analysis. 
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
OUTCOME OF PHARMACIST INTERVENTION IN EDUCATION OF 
PATIENTS ON DUPLICATE PRESCRIPING HYPNOTIC-SEDATIVES
Chu LL1, Lin HC1, Huang HY1, Chan AL2
1Chimei Medical Center, Tainan, Taiwan; 2Chi Mei Medical Center, Tainan, Taiwan
OBJECTIVES: The inappropriate uses of hypnotic-sedatives will likely cause drug 
abuse. It has been known that patients visit different hospitals back and forth to get 
a duplicate prescription of hypnotic-sedatives. The purpose of this study is to explore 
the decrease of reﬁ ll frequency of prescribing sedative-hypnotics and drug cost. 
METHODS: This is a cohort study. Adult patients, who were prescribed two or more 
than two sedative-hypnotics with same pharmacological mechanism over a week by 
different physicians, will be retrieved from the claim database of a medical center in 
southern Taiwan. The retrieved patients were received a questionnaire to evaluate 
their knowledge about the appropriate use of hypnotic-sedatives before clinical phar-
macists provided patients with education for appropriate use of hypnotic-sedatives. 
The primary outcome was the reduction of total consumption on hypnotic-sedatives 
and drug cost before and after pharmacist education. RESULTS: A total of 100 
patients were included in this study. The results showed that about 62.8% of patients 
with duplicate use of hypnotic-sedatives were female and 59.1% of patients aged ³50 
years. Their chief complains was insomnia and/or anxiety which cannot be relieved 
by taking only one hypnotic-sedatives. The most frequently prescribed drugs in their 
duplicate prescription were zolpidem (30.45%), Fludiazepam (22.34%), Alprazolam 
(14.9%), Flunitrazepam (8.45%), and Brotizolam (7.93%). The average total con-
sumption on hypnotic-sedatives per day for each patient was decreased from 1.68 to 
1.33 tablets. The monthly hypnotic-sedatives costs were reduced form NT$ 21,000 
to NT $ 15,600. CONCLUSIONS: Pharmacist education on the appropriate use of 
hypnotic-sedatives and lifestyle management is likely to reduce the total consumption 
on hypnotic-sedatives and save drug costs. 
PND2
WARFARIN-ASSOCIATED INTRACRANIAL HEMORRHAGE
Yang SC, Lin HL, Chan AL
Chi Mei Medical Center, Tainan, Taiwan
OBJECTIVES: To explore the possibility of international normalized ratio 
(INR),drug—warfarin interactions exaggerated intracerebral hemorrhage. 
METHODS: This is an observational study. Patients who had diagnoses of intracra-
nial hemorrhage (ICH,ICD-9-CM codes 430, 431, 432.0, 432.1, 432.9) from January 
2004 to December 2009 were retrieved from the claim database of a medical center 
in southern Taiwan. We reviewed medical records to identify the possible relationship 
with suspected risk factors, drug-warfarin interactions and ICH. Patients who were 
not taking warfarin at the time of hemorrhage and traumatic ICH were excluded. 
Potential drug interactions were deﬁ ned according to online drug interaction database 
of Lexi-InteractTM. Data were analyzed by multivariate logistic modeling. RESULTS: 
During the study period, 24 patients were deﬁ ned as ICH while patients were receiving 
warfarin. Forty-ﬁ ve percent of patients had an INR value >3.0 at admission to hospital 
and 25% were exceeded 5.0. The potential drug-warfarin interaction were antiplate-
lets (41.6%), allopurinol (16.6%), amiodarone (8.3%), NSAID (16.6%), others 
(16.6%).which may increased the bleeding risk. Five patients of 24 patients were died 
within 2 weeks. No correlation between the fatal cases and their gender, age, INR 
value, smoking, alcohol and comorbid diseases was founded. CONCLUSIONS: 
Although no correlation between drug–warfarin interaction, INR and ICH was found 
in this study, physicians should still need to inform patients, who are taking warfarin, 
to concern the potential interactions between herbs and over-the-counter medicines. 
NEUROLOGICAL DISORDERS – Cost Studies
PND3
A RAPID REVIEW OF ECONOMIC EVALAUTIONS OF DONEPEZIL, 
RIVASTIGMINE, GALANTAMINE AND MEMANTINE FOR ALZHEIMER’S 
DISEASE (AD)
Feng J, Huang R, Pwee K
Ministry of Health, Singapore
OBJECTIVES: To review the cost-effectiveness of cholinesterase inhibitors (ChEIs; 
donepezil, galantamine and rivastigmine) and memantine for treating patients with 
AD. This review aims to inform policymakers in Singapore on the published cost-
effectiveness studies of these drug therapies. METHODS: Electronic databases 
(EMBASE, MEDLINE, NHS EED) were searched from inception to February 2010 
for published economic evaluation studies. Additional references were identiﬁ ed 
through searching bibliographies of included studies and related publications. Review 
papers of economic evaluations either on individual drugs or more of these drugs were 
considered. An outline assessment of economic evaluations was undertaken using 
Drummond’s checklist. RESULTS: A systematic search of the literature identiﬁ ed 32 
economic evaluations (2 of all three ChEIs, 11 of donepezil, 5 of rivastigmine, 7 of 
galantamine, and 7 of memantine). All studies used clinical trial data from single drug 
comparisons with placebo. Different approaches have been used to model disease 
progression for evaluating cost-effectiveness of each drug, making comparison 
between drugs more difﬁ cult. Caro et al. (2003) and Green et al. (2005) considered 
the three ChEIs using a common analytical framework. Most of the studies reported 
that drugs provided health beneﬁ ts and cost savings over time, suggesting that their 
use was cost-effective. However, Green et al. (2005) concluded that treatment with 
ChEIs may not be cost effective from the UK NHS’s perspective. CONCLUSIONS: 
The majority of economic evaluations of ChEIs and memantine reported that these 
treatments were the dominant strategies compared with no treatment. However, 
conclusions from the reviews of economic analyses were mixed, and the authors com-
mented that the ﬁ ndings from economic analyses of these four drugs should be 
interpreted with caution due to the assumptions and methodology used. Comparison 
between studies is difﬁ cult due to difference in study types, geographic locations, 
perspectives and different assumptions within the models. 
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
PRS1
RISK OF SERIOUS ASTHMA EXACERBATIONS ASSOCIATED WITH 
LONG-ACTING-BETA-AGONISTS AMONG MEDICAID PATIENTS WITH 
ASTHMA: A RETROSPECTIVE COHORT STUDY
Guo JJ1, Tsai K2, Kelton CM3, Bian B1, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA; 2Novartis Pharmaceutical Company, East 
Hanover,, NJ, USA; 3University of Cincinnati College of Business, Cincinnati, OH, USA
OBJECTIVES: Concerns have been raised that the use of long-acting-beta-agonists 
(LABAs) may be associated with an increased risk of serious exacerbations (SAEs). 
We proposed to examine the association between LABAs and SAEs among patients 
with asthma in a large Medicaid population. METHODS: A total of 1,117,850 
patients with asthma were selected for this study using a multi-state Medicaid claims 
database. The study period was January 1, 2002 to December 31, 2007. SAEs included 
any primary asthma diagnosis for either hospitalization, emergency room visits, or 
intubation. Major asthma medications included in the analysis were inhaled cortico-
steroids (ICS), LABAs, ICS/LABA combinations, short-acting-beta-agonists, leukotri-
ene modiﬁ ers, and methylxanthines. Asthma severity levels were deﬁ ned by patient’s 
treatment regimens based on the national asthma guideline. Cox proportional hazard 
regression was conducted to assess the risk of SAEs associated with the use of LABAs, 
ICS/LABA combinations, and other covariates. RESULTS: Based on the ﬁ rst 6 months 
of wash-out period, we identiﬁ ed 550,392 patients with newly diagnosed and 567,458 
patients with preexisting asthma. A total of 197,283 (35.8%) newly diagnosed and 
242,207 (42.7%) preexisting patients had at least one SAE during the study period. 
After controlling for covariates, the risk of SAEs was relatively low among newly 
diagnosed patients taking salmeterol (hazard ratio [HR] = 0.93, 95% conﬁ dence 
intervals [CI] 0.89–0.97), formoterol (HR = 0.88, 0.83–0.94), and ICS/LABA combi-
nation (HR = 0.88, 0.87–0.90). Meanwhile, the risk of SAEs was mixed among pre-
existing asthmatic patients taking salmeterol (HR = 1.03, 1.01–1.04), formoterol (HR 
= 0.94, 0.90–0.97), and ICS/LABA combination (HR = 1.01, 1.00–1.02). Other key 
risk factors (P < 0.0001) were associated with African-American, severe or moderate 
asthma, use of oral steroids, alcohol or substance disorder, depressive disorder, preg-
nant women, obesity, and upper respiratory tract infection. CONCLUSIONS: The 
risk of SAEs should be considered when treating patients with asthma, especially for 
patients with key comorbidities as well as African-American patients and pregnant 
women. 
PRS4
ASSESSMENT OF KNOWLEDGE ABOUT TUBERCULOSIS AMONG TB 
PATIENTS IN NORTH EAST LIBYA
Solliman M1, Ahmad Hassali MA1, Al-Haddad M1, Hadidan M2
1Universiti Sains Malaysia, Penang, Penang, Malaysia, 2Alfatih Medical Sciences University, 
Tripoli, Libya
OBJECTIVES: To evaluate the knowledge toward the etiology and treatment of Tuber-
culosis (TB) among TB patients in North Eastern Libya. METHODS: Face to face 
interview with all TB Patients in 2009 was conducted at Kuwaiﬁ a and Shahat Chest 
Hospitals in North Eastern Libya. Questionnaire included questions related to the 
knowledge about transmission, diagnosis; risk factors, treatment and prevention of TB. 
A total of 140 patients participated in this study. Knowledge scores ranged from zero 
(minimum score) to 23 (maximum score). All data was analyzed using SPSS version 
15.00®. Inferential statistics were used as whenever appropriate. P-value of less than 
0.05 was considered signiﬁ cant. RESULTS: Majority of the respondents were Libyans 
(n = 92, 65.7%). Fifty-ﬁ ve (39.3%) of the respondents were males, and up to 90 subjects 
(64.3%) were urban residents. Almost all of the respondents have heard about TB. 
Nearly (n = 70, 50.0%) shared a thought that the main source of their knowledge 
regarding TB were health workers, followed by television (n = 63, 45.0%), and family 
members (n = 34, 24.3%). Libyans have signiﬁ cantly better knowledge (12.26 ± 4.33) 
than non Libyans (7.85 ± 4.83, t = 30.12, P < 0.001). In addition those respondents 
with tertiary educations scored signiﬁ cantly higher knowledge score (15.7 ± 4.2) com-
pared to those of intermediate (15.3 ± 3.8) and illiterate (9.4 ± 3.5), [F = 30.12, P = 
